Arvinas (ARVN) Net Equity Issued and Repurchased (2018 - 2020)
Arvinas' (ARVN) quarterly Net Equity Issued and Repurchased came in at $33.3 million in Q4 2020, up 11.25% quarter-over-quarter from $29.9 million in Q3 2020.
Arvinas (ARVN) Net Equity Issued and Repurchased (2018 - 2020) Analysis & Trends
Arvinas' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $33.3 million for Q4 2020.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $33.3 million in Q4 2020; TTM through Dec 2020 was $63.2 million, a N/A change from a year earlier, with the FY2020 full-year figure at $64.1 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased rose to $33.3 million in Q4 2020 per ARVN's latest filing, from $29.9 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $55.0 million in Q1 2018 and bottomed at $29.9 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 33.26 Mn |
| Dec 31, 2020 | 33.26 Mn |
| Sep 30, 2020 | 29.90 Mn |
| Sep 30, 2020 | 29.90 Mn |
| Mar 31, 2018 | 55.00 Mn |
| Mar 31, 2018 | 55.00 Mn |